Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00837902 · ClinicalTrials.gov registry record · NA
Genetic Determinants of Response to Beta Blockade
A NA study, sponsored by Vanderbilt University.
- Completed
- Registry status
- NA
- Development phase
- 154
- Enrollment target
NCT00837902 is a NA study that has completed, run by Vanderbilt University. The registered enrollment target is 154 participants.
The verdict
NCT00837902, a NA study, has completed, sponsored by Vanderbilt University.
- COMPLETED
- Registry status
- NA
- Development phase
- 154 participants
- Enrollment target
Study Summary
The overall goal of this project is to determine the genetic factors contributing to interindividual differences in response to beta-blockade.
Interventions
- DRUG Atenolol (β-blocker)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 154 participants |
| Start Date | 2009-01 |
| Est. Completion | 2014-12-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00837902
The ClinicalTrials.gov registry entry for NCT00837902 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 154 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University, which has 430 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Atenolol (β-blocker) is the first listed.
NCT00837902 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00837902 about?
NCT00837902 is a clinical study titled "Genetic Determinants of Response to Beta Blockade". The overall goal of this project is to determine the genetic factors contributing to interindividual differences in response to beta-blockade.
What is the current status of trial NCT00837902?
This trial is currently completed. It is a NA study. The enrollment target is 154 participants. The study started on 2009-01. Estimated completion is 2014-12-31.
What interventions are being tested in trial NCT00837902?
The interventions under investigation include: Atenolol (β-blocker) (DRUG).
Who is sponsoring clinical trial NCT00837902?
This trial is sponsored by Vanderbilt University, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.